Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

China · Delayed Price · Currency is CNY

9.19

+0.54 (6.24%)

Jun 29, 2026, 3:04 PM CST

-20.91% (1Y)

Market Cap	12.22B -21.0%
Revenue (ttm)	5.42B +2.1%
Net Income	380.47M -41.3%
EPS	0.26 -41.3%
Shares Out	1.47B
PE Ratio	35.44
Forward PE	15.84
Dividend	0.15 (1.68%)
Ex-Dividend Date	Jun 18, 2026

Volume	6,915,671
Open	8.65
Previous Close	8.65
Day's Range	8.50 - 9.22
52-Week Range	8.51 - 14.34
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Employees 2,150

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 002399

Full Company Profile

Financial Performance

In 2025, SHE:002399's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial Statements